Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–20 of 29 stories
The biopharma industry is increasingly focused on the weight loss sector, projected to surpass $130 billion by 2035. Analysts anticipate significant developments in the oral market and novel mechanisms as 2026 approaches.
Read full storyNovo Nordisk and Eli Lilly are competing in the rapidly growing obesity market, but the article argues that their approaches and products should not be directly compared. This highlights the diverse strategies within the sector as both companies seek to capture market share.
Eli Lilly executives view the successful launch of Novo Nordisk's Wegovy pill as a positive indicator for their own obesity treatment, orforglipron, anticipated to launch in Q2. This sentiment reflects confidence in the competitive landscape for weight management therapies.
Amgen is developing MariTide, an investigational obesity drug that aims to offer competitive weight loss results with extended dosing intervals of a month or longer. This approach could potentially shift the treatment paradigm for obesity management.
GSK shifts its strategy away from the competitive GLP-1 market to focus on downstream effects of obesity, particularly with its Phase III-ready FGF21 analog efimosfermin alfa targeting liver fibrosis. This decision highlights GSK's commitment to addressing obesity-related complications rather than weight loss alone.
A case report highlights the complexities of managing a large hiatal hernia in a patient with bulimia nervosa and obesity. This interdisciplinary approach underscores the need for tailored treatment strategies in rare disease presentations.
Pfizer's early data on its obesity candidate Metsera has left analysts seeking more information following the company's fourth-quarter earnings call. The limited insights provided have raised questions about the drug's potential and market positioning.
Pfizer's stock dipped following Phase 2 trial results indicating that its long-acting obesity drug, acquired through a $10 billion deal with Metsera, is 'slightly inferior' to Eli Lilly's leading Zepbound. This development raises concerns about the competitive positioning of Pfizer's new asset in the obesity market.
Pfizer reports promising mid-stage trial results for PF’3944, demonstrating weight loss of up to 12.3% at 28 weeks. This data positions Pfizer competitively in the obesity treatment market following its acquisition of Metsera.
Novo Nordisk's next-generation obesity drug, CagriSema, outperformed Wegovy in blood sugar control during a Phase III trial, although it did not achieve the 25% weight loss target. This development could impact the competitive landscape for obesity treatments.
Novo Nordisk's CagriSema demonstrates superior blood sugar and weight reduction compared to Wegovy in a recent diabetes trial. However, it may face challenges competing against Eli Lilly's Zepbound in the obesity market.
Eli Lilly invests $3.5 billion to establish a plant in Pennsylvania dedicated to producing injectable obesity drugs, including tirzepatide and retatrutide, set to begin operations in 2031. This initiative is part of Lilly's broader $50 billion reshoring strategy.
AstraZeneca has entered a significant alliance with China's CSPC to develop up to eight next-generation weight loss medications, potentially worth over $18 billion. This deal marks the largest licensing agreement in the obesity treatment space since 2025.
The CDC has released new guidelines addressing obesity and overweight, emphasizing the need for comprehensive strategies to combat these conditions. The guidelines aim to inform policy decisions and public health initiatives.
Recent CDC data reveals that obesity rates remain high across all states, with no state achieving the Healthy People 2010 goal of reducing adult obesity prevalence to 15%. This highlights the ongoing public health challenge posed by obesity in the U.S.
A CDC report reveals that the number of U.S. states with an obesity prevalence of 30% or more has tripled to nine states in 2009. This highlights a growing public health concern that may impact healthcare policies and patient advocacy efforts.
The CDC reports that the Southeast, Appalachia, and certain tribal lands have the highest rates of obesity and diabetes in the U.S. This data highlights significant health disparities that may require targeted public health interventions.
The CDC awarded eight organizations with the Pioneering Innovation Award at the Weight of the Nation Conference, recognizing their innovative initiatives in obesity prevention and control. This highlights ongoing efforts to address obesity as a significant public health issue.
The CDC convened its inaugural 'Weight of the Nation' conference to address the obesity crisis in the U.S., focusing on prevention strategies across communities, medical care, schools, and workplaces. The event aims to highlight progress and overcome barriers to obesity prevention.
A new study estimates that the medical cost of obesity in the U.S. could reach $147 billion annually. Conducted by the Research Triangle Institute and the CDC, this research highlights the significant financial burden of obesity on the healthcare system.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.